Agomab doses first patient in NOV — ERA Phase 2b trial of ontunisertib in fibrostenosing Crohn’s disease

Agomab began dosing in NOV-ERA, a global Phase 2b trial of ontunisertib for symptomatic fibrostenosing Crohn’s disease. Earlier Phase 2a STENOVA results were already presented, supporting continued late-stage development of the anti-fibrotic program. The study will test whether ontunisertib improves bowel narrowing outcomes versus placebo, with readouts expected in the future. NOV-ERA targets about 320 patients, a scale-up that positions ontunisertib as a potential first targeted therapy for fibrosis in Crohn’s. Trial start triggers a EUR 7 million milestone tied to Agomab’s Origo Biopharma acquisition, lifting payable milestones to EUR 10 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via (Ref. ID: 202610131605PRIMZONEFULLFEED1001277611) on October 13, 2026, and is solely responsible for the information contained therein. (C) Cop